Duchesnay Drug Patent Portfolio

Duchesnay owns 3 orange book drugs protected by 14 US patents Given below is the list of Duchesnay's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9089489 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
Active
US9375404 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
Active
US9526703 Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
Active
US9937132 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
Active
US8642079 Solid formulations of ospemifene 09 Jul, 2028
Active
US8236861 Method for enhancing the bioavailablity of ospemifene 11 Aug, 2026
Active
US6245819 Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause 21 Jul, 2025
Active
US8470890 Method for enhancing the bioavailability of ospemifene 13 Feb, 2024 Expired
US8772353 Method for enhancing the bioavalability of ospemifene 13 Feb, 2024 Expired
US9241915 Method for enhancing the bioavailability of ospemifene 13 Feb, 2024 Expired
US9855224 Method for enhancing the bioavailability of ospemifene 13 Feb, 2024 Expired
US9566252 Method for the alleviation of dyspareunia in women 02 Nov, 2022 Expired
US6340695 Rapid onset formulation 21 Jun, 2021 Expired
US7560122 Pharmaceutical dosage form bearing pregnancy-friendly indicia 25 Jan, 2019 Expired


Given below is the list of recent legal activities going on the following drug patents of Duchesnay.

Activity Date Patent Number
Patent litigations
Expire Patent 04 Mar, 2024 US9241915
Payment of Maintenance Fee, 12th Year, Large Entity 07 Feb, 2024 US8236861
Payment of Maintenance Fee, 8th Yr, Small Entity 15 Jan, 2024 US9526703
Maintenance Fee Reminder Mailed 18 Sep, 2023 US9241915
Payment of Maintenance Fee, 8th Yr, Small Entity 26 Jul, 2023 US9375404
Payment of Maintenance Fee, 8th Yr, Small Entity 12 Dec, 2022 US9089489
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jan, 2022 US8772353
Payment of Maintenance Fee, 4th Yr, Small Entity 29 Sep, 2021 US9937132
Expire Patent 16 Aug, 2021 US7560122
Expire Patent 16 Aug, 2021 US7560122
Payment of Maintenance Fee, 8th Year, Large Entity 08 Jul, 2021 US8642079
Payment of Maintenance Fee, 4th Year, Large Entity 23 Jun, 2021 US9855224
Maintenance Fee Reminder Mailed 01 Mar, 2021 US7560122
Maintenance Fee Reminder Mailed 01 Mar, 2021 US7560122
Payment of Maintenance Fee, 8th Year, Large Entity 16 Oct, 2020 US8470890


Duchesnay's Drug Patent Litigations

Duchesnay's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 19, 2013, against patent number US9566252. The petitioner , challenged the validity of this patent, with Kaija Halonen et al as the respondent. Click below to track the latest information on how companies are challenging Duchesnay's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9566252 August, 2013 Decision
(06 Jul, 2016)
Kaija Halonen et al


Duchesnay's Family Patents

Duchesnay drugs have patent protection in a total of 42 countries. It's US patent count contributes only to 12.4% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Duchesnay Drug List

Given below is the complete list of Duchesnay's drugs and the patents protecting them.


1. Bonjesta

Bonjesta is protected by 5 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9089489 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
(8 years from now)
Active
US9375404 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
(8 years from now)
Active
US9526703 Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
(8 years from now)
Active
US9937132 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof 18 Feb, 2033
(8 years from now)
Active
US7560122 Pharmaceutical dosage form bearing pregnancy-friendly indicia 25 Jan, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bonjesta's drug page


2. Diclegis

Diclegis is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6340695 Rapid onset formulation 21 Jun, 2021
(3 years ago)
Expired
US7560122 Pharmaceutical dosage form bearing pregnancy-friendly indicia 25 Jan, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diclegis's drug page


3. Osphena

Osphena is protected by 8 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8642079 Solid formulations of ospemifene 09 Jul, 2028
(3 years from now)
Active
US8236861 Method for enhancing the bioavailablity of ospemifene 11 Aug, 2026
(1 year, 10 months from now)
Active
US6245819 Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause 21 Jul, 2025
(9 months from now)
Active
US8470890 Method for enhancing the bioavailability of ospemifene 13 Feb, 2024
(7 months ago)
Expired
US8772353 Method for enhancing the bioavalability of ospemifene 13 Feb, 2024
(7 months ago)
Expired
US9241915 Method for enhancing the bioavailability of ospemifene 13 Feb, 2024
(7 months ago)
Expired
US9855224 Method for enhancing the bioavailability of ospemifene 13 Feb, 2024
(7 months ago)
Expired
US9566252 Method for the alleviation of dyspareunia in women 02 Nov, 2022
(1 year, 11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Osphena's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List